Compare · ANTM vs VRDN
ANTM vs VRDN
Side-by-side comparison of Anthem Inc. (ANTM) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTM and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ANTM is the larger of the two at $107.30B, about 61.2x VRDN ($1.75B).
- VRDN has hit the wire 15 times in the past 4 weeks while ANTM has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Anthem Inc.
- Viridian Therapeutics Inc.
- Price
- -
- -
- Market cap
- $107.30B
- $1.75B
- 1M return
- -
- +7.90%
- 1Y return
- -
- +29.95%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 15
- Recent ratings
- 25
- 25
Anthem Inc.
Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest ANTM
- SEC Form 4: Todt Blair Williams was granted 3,983 shares, increasing direct ownership by 93% to 8,283 units
- SEC Form 4: Norwood Felicia F covered exercise/tax liability with 1,754 shares, decreasing direct ownership by 6% to 26,684 units
- SEC Form 4: Todt Blair Williams covered exercise/tax liability with 117 shares, decreasing direct ownership by 3% to 4,300 units
- SEC Form 4: Boudreaux Gail gifted 10,000 shares, decreasing direct ownership by 8% to 111,415 units
- Anthem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4: Kendrick Charles Morgan Jr covered exercise/tax liability with 79 shares, decreasing direct ownership by 0.54% to 14,450 units
- SEC Form 4: Haytaian Peter D covered exercise/tax liability with 200 shares, decreasing direct ownership by 2% to 11,961 units
- SEC Form 4: Strable-Soethout Deanna D was granted 200 shares
- SEC Form 3 filed by new insider Strable-Soethout Deanna D
- SEC Form 424B3 filed by Anthem Inc.
Latest VRDN
- SEC Form FWP filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.
- SEC Form 305B2 filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
- Viridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 10-Q filed by Viridian Therapeutics Inc.